Coxevac

inactivated Coxiella burnetii vaccine

Table of contents

Opinion

On 15 February 2023, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of an extension to the terms of the marketing authorisation for the veterinary medicinal product Coxevac. The marketing authorisation holder for this veterinary medicinal product is CEVA Santé Animale.

Coxevac is currently authorised as suspension for injection for cattle and goats. The extension concerns the addition of sheep as a target species.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.


1 Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Key facts

Name
Coxevac
Agency product number
EMEA/V/C/000155
International non-proprietary name (INN) or common name
  • inactivated Coxiella burnetii vaccine
Species
Goats
Cattle
Active substance
  • inactivated Coxiella burnetii vaccine, strain Nine Mile
Date opinion adopted
15/02/2023
Company name
CEVA Santé Animale
Status
Positive
Application type
Post-authorisation

Related content

How useful was this page?

Add your rating